Moderna, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on ...

Have you assessed how the international operations of Moderna (MRNA) performed in the quarter ended December 2024? For this biotechnology company, possessing an expansive global footprint ...

U.S. health officials are reevaluating a $590M bird flu vaccine contract that was awarded to Moderna (NASDAQ:MRNA) by the ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

(Reuters) - U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna (NASDAQ: MRNA) for the ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But ...

Allspring Global Investments Holdings LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.2% in the fourth quarter, Holdings Channel reports. The firm owned 15,368 shares of ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...

Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...